JP2015015964A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015015964A5 JP2015015964A5 JP2014209206A JP2014209206A JP2015015964A5 JP 2015015964 A5 JP2015015964 A5 JP 2015015964A5 JP 2014209206 A JP2014209206 A JP 2014209206A JP 2014209206 A JP2014209206 A JP 2014209206A JP 2015015964 A5 JP2015015964 A5 JP 2015015964A5
- Authority
- JP
- Japan
- Prior art keywords
- hmgcb
- preparation
- mannose residues
- sugar chains
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims 33
- 125000000311 mannosyl group Chemical group C1([C@@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims 32
- 210000004027 cell Anatomy 0.000 claims 27
- 102000004547 Glucosylceramidase Human genes 0.000 claims 11
- 108010017544 Glucosylceramidase Proteins 0.000 claims 11
- 229920001542 oligosaccharide Polymers 0.000 claims 11
- 150000002482 oligosaccharides Chemical class 0.000 claims 11
- 239000002243 precursor Substances 0.000 claims 11
- 208000015872 Gaucher disease Diseases 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- FXUAIOOAOAVCGD-FKSUSPILSA-N swainsonine Chemical compound C1CC[C@H](O)[C@H]2[C@H](O)[C@H](O)CN21 FXUAIOOAOAVCGD-FKSUSPILSA-N 0.000 claims 5
- 229960005566 swainsonine Drugs 0.000 claims 5
- FXUAIOOAOAVCGD-UHFFFAOYSA-N swainsonine Natural products C1CCC(O)C2C(O)C(O)CN21 FXUAIOOAOAVCGD-UHFFFAOYSA-N 0.000 claims 5
- 108091026890 Coding region Proteins 0.000 claims 4
- 230000001105 regulatory effect Effects 0.000 claims 4
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims 3
- 102000001696 Mannosidases Human genes 0.000 claims 2
- 108010054377 Mannosidases Proteins 0.000 claims 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
- 206010031264 Osteonecrosis Diseases 0.000 claims 2
- 238000001990 intravenous administration Methods 0.000 claims 2
- 239000002603 mannosidase inhibitor Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 150000007523 nucleic acids Chemical group 0.000 claims 2
- 238000007911 parenteral administration Methods 0.000 claims 2
- 208000000187 Abnormal Reflex Diseases 0.000 claims 1
- 208000010392 Bone Fractures Diseases 0.000 claims 1
- 206010006002 Bone pain Diseases 0.000 claims 1
- 206010012559 Developmental delay Diseases 0.000 claims 1
- 206010017076 Fracture Diseases 0.000 claims 1
- 208000020322 Gaucher disease type I Diseases 0.000 claims 1
- 208000020916 Gaucher disease type II Diseases 0.000 claims 1
- 208000028735 Gaucher disease type III Diseases 0.000 claims 1
- 208000009612 Laryngismus Diseases 0.000 claims 1
- 206010023891 Laryngospasm Diseases 0.000 claims 1
- 208000029725 Metabolic bone disease Diseases 0.000 claims 1
- 206010054107 Nodule Diseases 0.000 claims 1
- 206010049088 Osteopenia Diseases 0.000 claims 1
- 206010061363 Skeletal injury Diseases 0.000 claims 1
- 208000004350 Strabismus Diseases 0.000 claims 1
- 208000007502 anemia Diseases 0.000 claims 1
- 230000000692 anti-sense effect Effects 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002996 emotional effect Effects 0.000 claims 1
- 210000002950 fibroblast Anatomy 0.000 claims 1
- 206010019847 hepatosplenomegaly Diseases 0.000 claims 1
- 210000005260 human cell Anatomy 0.000 claims 1
- 206010020745 hyperreflexia Diseases 0.000 claims 1
- 230000035859 hyperreflexia Effects 0.000 claims 1
- 208000019423 liver disease Diseases 0.000 claims 1
- 230000005976 liver dysfunction Effects 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 210000003098 myoblast Anatomy 0.000 claims 1
- 230000003393 splenic effect Effects 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 206010043554 thrombocytopenia Diseases 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/641,471 US7138262B1 (en) | 2000-08-18 | 2000-08-18 | High mannose proteins and methods of making high mannose proteins |
| US09/641,471 | 2000-08-18 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011173243A Division JP5683407B2 (ja) | 2000-08-18 | 2011-08-08 | 高マンノースタンパク質および高マンノースタンパク質の製造方法 |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016089304A Division JP6659443B2 (ja) | 2000-08-18 | 2016-04-27 | 高マンノースタンパク質および高マンノースタンパク質の製造方法 |
| JP2018000449A Division JP6626133B2 (ja) | 2000-08-18 | 2018-01-05 | 高マンノースタンパク質および高マンノースタンパク質の製造方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015015964A JP2015015964A (ja) | 2015-01-29 |
| JP2015015964A5 true JP2015015964A5 (cg-RX-API-DMAC7.html) | 2015-11-05 |
Family
ID=24572532
Family Applications (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002520848A Expired - Lifetime JP5008245B2 (ja) | 2000-08-18 | 2001-08-17 | 高マンノースタンパク質および高マンノースタンパク質の製造方法 |
| JP2011173243A Expired - Fee Related JP5683407B2 (ja) | 2000-08-18 | 2011-08-08 | 高マンノースタンパク質および高マンノースタンパク質の製造方法 |
| JP2011173242A Expired - Fee Related JP5840890B2 (ja) | 2000-08-18 | 2011-08-08 | 高マンノースタンパク質および高マンノースタンパク質の製造方法 |
| JP2014209206A Pending JP2015015964A (ja) | 2000-08-18 | 2014-10-10 | 高マンノースタンパク質および高マンノースタンパク質の製造方法 |
| JP2016089304A Expired - Lifetime JP6659443B2 (ja) | 2000-08-18 | 2016-04-27 | 高マンノースタンパク質および高マンノースタンパク質の製造方法 |
| JP2018000449A Expired - Lifetime JP6626133B2 (ja) | 2000-08-18 | 2018-01-05 | 高マンノースタンパク質および高マンノースタンパク質の製造方法 |
| JP2018090467A Expired - Lifetime JP6681428B2 (ja) | 2000-08-18 | 2018-05-09 | 高マンノースタンパク質および高マンノースタンパク質の製造方法 |
Family Applications Before (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002520848A Expired - Lifetime JP5008245B2 (ja) | 2000-08-18 | 2001-08-17 | 高マンノースタンパク質および高マンノースタンパク質の製造方法 |
| JP2011173243A Expired - Fee Related JP5683407B2 (ja) | 2000-08-18 | 2011-08-08 | 高マンノースタンパク質および高マンノースタンパク質の製造方法 |
| JP2011173242A Expired - Fee Related JP5840890B2 (ja) | 2000-08-18 | 2011-08-08 | 高マンノースタンパク質および高マンノースタンパク質の製造方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016089304A Expired - Lifetime JP6659443B2 (ja) | 2000-08-18 | 2016-04-27 | 高マンノースタンパク質および高マンノースタンパク質の製造方法 |
| JP2018000449A Expired - Lifetime JP6626133B2 (ja) | 2000-08-18 | 2018-01-05 | 高マンノースタンパク質および高マンノースタンパク質の製造方法 |
| JP2018090467A Expired - Lifetime JP6681428B2 (ja) | 2000-08-18 | 2018-05-09 | 高マンノースタンパク質および高マンノースタンパク質の製造方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US7138262B1 (cg-RX-API-DMAC7.html) |
| EP (3) | EP1309340B1 (cg-RX-API-DMAC7.html) |
| JP (7) | JP5008245B2 (cg-RX-API-DMAC7.html) |
| CN (4) | CN102559633A (cg-RX-API-DMAC7.html) |
| AU (1) | AU785460B2 (cg-RX-API-DMAC7.html) |
| CA (3) | CA2388041C (cg-RX-API-DMAC7.html) |
| HK (1) | HK1205183A1 (cg-RX-API-DMAC7.html) |
| IL (2) | IL149029A0 (cg-RX-API-DMAC7.html) |
| MX (1) | MXPA02003894A (cg-RX-API-DMAC7.html) |
| NZ (2) | NZ537128A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2002015927A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL155588A0 (en) * | 2003-04-27 | 2003-11-23 | Metabogal Ltd | Methods for expression of enzymatically active recombinant lysosomal enzymes in transgenic plant root cells and vectors used thereby |
| US7138262B1 (en) * | 2000-08-18 | 2006-11-21 | Shire Human Genetic Therapies, Inc. | High mannose proteins and methods of making high mannose proteins |
| US7951557B2 (en) | 2003-04-27 | 2011-05-31 | Protalix Ltd. | Human lysosomal proteins from plant cell culture |
| US20050137223A1 (en) * | 2003-11-12 | 2005-06-23 | Amicus Therapeutics, Inc. | Glucoimidazole and polyhydroxycyclohexenyl amine derivatives to treat gaucher disease |
| EP1866071A4 (en) * | 2005-03-03 | 2013-04-24 | Univ Indiana Res & Tech Corp | PERMETHYLATION OF OLIGOSACCHARIDES |
| CA2601797A1 (en) * | 2005-03-16 | 2006-09-21 | University Of Oxford | Mannose immunogens for hiv-1 |
| WO2006110277A1 (en) | 2005-04-11 | 2006-10-19 | Medarex, Inc. | Protein purification using hcic amd ion exchange chromatography |
| US8202523B2 (en) | 2005-09-22 | 2012-06-19 | ProSci, Inc. | Glycosylated polypeptides produced in yeast mutants and methods of use thereof |
| DK1945665T3 (da) * | 2005-10-21 | 2012-02-06 | Genzyme Corp | Antistof-baserede terapimidler med forhøjet ADCC-aktivitet |
| ES2391657T3 (es) | 2006-02-07 | 2012-11-28 | Shire Human Genetic Therapies, Inc. | Composiciones estabilizadas de proteínas que tienen un resto tiol libre |
| EP2102335B1 (en) * | 2007-01-04 | 2012-02-22 | Crucell Holland B.V. | Purification of factor xi |
| ES2660667T3 (es) | 2007-05-07 | 2018-03-23 | Protalix Ltd. | Biorreactor desechable a gran escala |
| AU2010281403B2 (en) | 2009-07-28 | 2016-03-10 | Takeda Pharmaceutical Company Limited | Compositions and methods for treating Gaucher disease |
| WO2011019620A1 (en) | 2009-08-10 | 2011-02-17 | Genentech, Inc. | Antibodies with enhanced adcc function |
| CA2773133A1 (en) | 2009-08-28 | 2011-03-03 | Edward H. Schuchman | Dose escalation enzyme replacement therapy for treating acid sphingomyelinase deficiency |
| CA2790786C (en) * | 2010-02-24 | 2019-09-24 | Zymenex A/S | Process for production and purification of recombinant lysosomal alpha-mannosidase |
| WO2012012461A2 (en) | 2010-07-19 | 2012-01-26 | Shire Human Genetic Therapies, Inc. | Mannose receptor c type 1 (mrc1) codon optimized cell line and uses thereof |
| CN103154243A (zh) | 2010-10-15 | 2013-06-12 | 日本化学研究株式会社 | 糖链的非还原末端为甘露糖残基的糖蛋白的制造方法 |
| SG10201605874TA (en) | 2011-04-22 | 2016-09-29 | Genzyme Corp | Modified acid alpha glucosidase with accelerated processing |
| WO2013055888A2 (en) | 2011-10-12 | 2013-04-18 | Synageva Biopharma Corp. | Recombinant human naglu protein and uses thereof |
| EP2606741B1 (en) * | 2011-12-23 | 2014-04-16 | Foodip Sarl | Glycoprotein enriched composition as a food and feed additive and/or as a therapeutic agent |
| WO2013130963A1 (en) | 2012-03-02 | 2013-09-06 | Shire Human Genetic Therapies, Inc. | Compositions and methods for treating type iii gaucher disease |
| CN102827212B (zh) * | 2012-07-25 | 2015-04-15 | 中国科学院海洋研究所 | 一种乙酰化壳三糖的制备方法 |
| TWI793159B (zh) * | 2013-10-23 | 2023-02-21 | 美商健臻公司 | 重組醣蛋白及其用途 |
| SI3063287T1 (sl) * | 2013-10-31 | 2025-06-30 | Amgen, Inc. | Uporaba monenzina za regulacijo glikozilacije rekombinantnih proteinov |
| AU2015323966A1 (en) | 2014-09-29 | 2017-03-16 | Alexion Pharmaceuticals, Inc. | Methods of treating mucopolysaccharidosis IIIB (MPSIIIB) |
| KR102803158B1 (ko) | 2015-12-02 | 2025-05-08 | 주식회사 에스티큐브앤컴퍼니 | Btn1a1에 면역특이적으로 결합하는 항체와 분자 및 그의 치료 용도 |
| CN108795871B (zh) * | 2017-04-28 | 2021-12-03 | 江南大学 | 用于生产糖蛋白的动物细胞株及方法、糖蛋白及其用途 |
| CN111051346A (zh) | 2017-05-31 | 2020-04-21 | 斯特库伯株式会社 | 使用免疫特异性结合btn1a1的抗体和分子治疗癌症的方法 |
| CN111148762A (zh) | 2017-05-31 | 2020-05-12 | 斯特库伯株式会社 | 免疫特异性结合至btn1a1的抗体和分子及其治疗性用途 |
| JP2020522562A (ja) | 2017-06-06 | 2020-07-30 | ストキューブ アンド シーオー., インコーポレイテッド | Btn1a1又はbtn1a1リガンドに結合する抗体及び分子を用いて癌を治療する方法 |
| CN108179160B (zh) * | 2018-01-29 | 2021-05-11 | 江南大学 | 一种植烷醇连接的高甘露糖型寡糖的制备方法 |
| CN108588127A (zh) * | 2018-04-11 | 2018-09-28 | 上海药明生物技术有限公司 | 一种表达高甘露糖糖型的葡萄糖脑苷脂酶的细胞株及其制备方法和应用 |
| CN113795575A (zh) * | 2019-02-04 | 2021-12-14 | 自由行疗法有限公司 | 多核苷酸 |
| CN119530200A (zh) * | 2024-11-28 | 2025-02-28 | 北海康成(苏州)生物制药有限公司 | 一种维拉苷酶β的纯化方法和药液 |
Family Cites Families (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US5272066A (en) | 1986-03-07 | 1993-12-21 | Massachusetts Institute Of Technology | Synthetic method for enhancing glycoprotein stability |
| US4925796A (en) | 1986-03-07 | 1990-05-15 | Massachusetts Institute Of Technology | Method for enhancing glycoprotein stability |
| WO1989005850A1 (en) * | 1987-12-23 | 1989-06-29 | The United States Of America, As Represented By Th | Cloned dna for synthesizing unique glucocerebrosidase |
| US5549892A (en) | 1988-12-23 | 1996-08-27 | Genzyme Corporation | Enhanced in vivo uptake of glucocerebrosidase |
| JPH03503721A (ja) | 1988-12-23 | 1991-08-22 | ジェンザイム コーポレイション | 酵素的に活性な組換えグルコセレブロシダーゼ |
| US5236838A (en) | 1988-12-23 | 1993-08-17 | Genzyme Corporation | Enzymatically active recombinant glucocerebrosidase |
| JP2893481B2 (ja) | 1988-12-23 | 1999-05-24 | ジェンザイム コーポレイション | 酵素的に活性な組換えグルコセレブロシダーゼ |
| US5401650A (en) | 1990-10-24 | 1995-03-28 | The Mount Sinai School Of Medicine Of The City University Of New York | Cloning and expression of biologically active α-galactosidase A |
| EP0568647B1 (en) | 1991-01-21 | 1996-09-11 | Genzyme Corporation | Production of enzymatically active glucocerebrosidase from recombinant cells |
| US5968502A (en) | 1991-11-05 | 1999-10-19 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
| US6270989B1 (en) * | 1991-11-05 | 2001-08-07 | Transkaryotic Therapies, Inc. | Protein production and delivery |
| US5641670A (en) | 1991-11-05 | 1997-06-24 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
| US5911983A (en) | 1992-06-26 | 1999-06-15 | University Of Pittsburgh | Gene therapy for Gaucher disease using retroviral vectors |
| CA2150956A1 (en) | 1992-12-10 | 1994-06-23 | Robert G. L. Shorr | Glycolipid enzyme-polymer conjugates |
| WO1994014837A1 (en) | 1992-12-21 | 1994-07-07 | Enzon, Inc. | Purification of proteinaceous material |
| JP3002113B2 (ja) | 1994-03-30 | 2000-01-24 | 寳酒造株式会社 | 糖質又は複合糖質の製造方法 |
| EP0675204B1 (en) | 1994-03-30 | 2001-05-30 | Takara Shuzo Co. Ltd. | Transglycosylating process for producing carbohydrates or glycoconjugates |
| US5670132A (en) | 1994-09-20 | 1997-09-23 | Immunomedics, Inc. | Modified radioantibody fragments for reduced renal uptake |
| EP0865499B1 (en) * | 1995-09-14 | 2009-03-18 | Virginia Tech Intellectual Properties, Inc. | Production of lysosomal enzymes in plant-based expression systems |
| WO1997032591A1 (en) | 1996-03-05 | 1997-09-12 | Orquest, Inc. | Method of promoting bone growth with hyaluronic acid and growth factors |
| US6177447B1 (en) * | 1996-07-15 | 2001-01-23 | Universiteit Van Amsterdam | Deoxynojirimycin derivatives and their uses as glucosylceramidase inhibitors |
| NZ506214A (en) * | 1996-09-13 | 2002-11-26 | Transkaryotic Therapies Inc | Therapy for alpha-galactosidase A deficiency |
| EP0852951A1 (de) | 1996-11-19 | 1998-07-15 | Roche Diagnostics GmbH | Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern |
| JPH10273500A (ja) | 1997-03-03 | 1998-10-13 | Noguchi Inst | 複合糖ペプチド及びその製造法 |
| JPH10306099A (ja) | 1997-03-04 | 1998-11-17 | Noguchi Inst | 新規複合糖ペプチドおよびその製法 |
| TW542721B (en) | 1997-08-06 | 2003-07-21 | Melaleuca Inc | Dietary supplements containing natural ingredients |
| DE69825288D1 (de) | 1997-08-07 | 2004-09-02 | Univ Utah | Prodrugs und konjugate von selenolenthaltenden verbindungen und ihre verwendung |
| US5939279A (en) * | 1997-09-18 | 1999-08-17 | The Board Of Trustees Of The University Of Arkansas | Inhibition of bacterial binding by high-mannose oligosaccharides |
| EP1041996A4 (en) | 1997-12-22 | 2003-05-14 | Human Genome Sciences Inc | KERATINOCYTE GROWTH FACTOR-2 FORMULATIONS |
| GB9802249D0 (en) | 1998-02-03 | 1998-04-01 | Ciba Geigy Ag | Organic compounds |
| GB9807464D0 (en) | 1998-04-07 | 1998-06-10 | Pharming Bv | Purification of human acid µ-glucosidase |
| EP0976838A1 (en) | 1998-05-06 | 2000-02-02 | Rhone-Poulenc Nutrition Animale | Enzymes mixture |
| JPH11318441A (ja) | 1998-05-14 | 1999-11-24 | Nagase & Co Ltd | 超耐熱耐酸性アミロプルラナーゼ |
| KR19990086271A (ko) | 1998-05-27 | 1999-12-15 | 손경식 | 면역세포의 신규한 엔도뉴클레아제 및 이를 사용한 면역보조제 |
| KR20010052499A (ko) | 1998-06-05 | 2001-06-25 | 아방티 파르마 소시에테 아노님 | 베타-시크리타제형 활성을 지닌 폴리펩타이드 |
| PT1137789E (pt) * | 1998-12-09 | 2010-10-21 | Phyton Holdings Llc | Um método para produzir glicoproteínas possuindo glicosilação de tipo humano |
| GB9909066D0 (en) | 1999-04-20 | 1999-06-16 | Oxford Glycosciences Uk Ltd | Therapies |
| EP1189599A2 (en) | 1999-06-11 | 2002-03-27 | Eli Lilly And Company | Pharmaceutical materials and methods for their preparation and use |
| JP2003505430A (ja) | 1999-07-26 | 2003-02-12 | ジー・ディー・サール・アンド・カンパニー | デオキシノジリマイシンの長鎖n−アルキル誘導体およびグルコセレブロシダーゼ酵素の糖脂質異常蓄積疾患の治療用の薬剤の製造のための使用 |
| US6770468B1 (en) | 1999-09-14 | 2004-08-03 | Genzyme Glycobiology Research Institute, Inc. | Phosphodiester-α-GlcNAcase of the lysosomal targeting pathway |
| US6534300B1 (en) | 1999-09-14 | 2003-03-18 | Genzyme Glycobiology Research Institute, Inc. | Methods for producing highly phosphorylated lysosomal hydrolases |
| IL150314A0 (en) | 1999-12-30 | 2002-12-01 | Maxygen Aps | Improved lysosomal enzymes and lysosomal enzyme activators |
| US20040204379A1 (en) | 2000-06-19 | 2004-10-14 | Cheng Seng H. | Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases |
| US20020095135A1 (en) * | 2000-06-19 | 2002-07-18 | David Meeker | Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases |
| US7138262B1 (en) | 2000-08-18 | 2006-11-21 | Shire Human Genetic Therapies, Inc. | High mannose proteins and methods of making high mannose proteins |
| CN1156702C (zh) | 2001-07-11 | 2004-07-07 | 上海晶泰生物技术有限公司 | 采用标记链霉亲和素-生物素技术的蛋白质芯片 |
| US20040202666A1 (en) | 2003-01-24 | 2004-10-14 | Immunomedics, Inc. | Anti-cancer anthracycline drug-antibody conjugates |
| JP5589165B2 (ja) | 2003-01-31 | 2014-09-17 | マウント シナイ スクール オブ メディシン オブ ニューヨーク ユニバーシティー | タンパク質欠損性障害の治療のための併用療法 |
| US20060008415A1 (en) | 2004-06-25 | 2006-01-12 | Protein Design Labs, Inc. | Stable liquid and lyophilized formulation of proteins |
| NZ555308A (en) | 2004-12-22 | 2010-10-29 | Ambrx Inc | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides |
| WO2007019232A2 (en) | 2005-08-03 | 2007-02-15 | Immunogen, Inc. | Immunoconjugate formulations |
| ES2391657T3 (es) | 2006-02-07 | 2012-11-28 | Shire Human Genetic Therapies, Inc. | Composiciones estabilizadas de proteínas que tienen un resto tiol libre |
| ES2366059T3 (es) | 2006-03-17 | 2011-10-14 | Biomarin Pharmaceutical Inc. | Ensayos para la detección de anticuerpos anti-enzimas lisosómicas. |
| NZ572226A (en) | 2006-04-18 | 2011-05-27 | Ekr Therapeutics Inc | Pre-mixed, ready-to-use IV bolus compositions comprising nicardipine and methods of use |
| DK2040548T3 (da) | 2006-06-23 | 2012-08-13 | Amicus Therapeutics Inc | Fremgangsmåde til behandling af neurologiske forstyrrelser ved forøgelse af aktiviteten af beta-glucocerebrosidase |
| DK2041270T3 (da) | 2006-07-13 | 2014-01-27 | Wyeth Llc | Fremstilling af glycoproteiner |
| TWI489984B (zh) | 2006-08-04 | 2015-07-01 | Wyeth Corp | 用於非經腸道傳輸化合物之配方及其用途 |
| AU2010281403B2 (en) | 2009-07-28 | 2016-03-10 | Takeda Pharmaceutical Company Limited | Compositions and methods for treating Gaucher disease |
| US20130017169A1 (en) | 2010-03-02 | 2013-01-17 | Protalix Ltd. | Multimeric forms of therapeutic proteins and uses thereof |
| WO2012012461A2 (en) | 2010-07-19 | 2012-01-26 | Shire Human Genetic Therapies, Inc. | Mannose receptor c type 1 (mrc1) codon optimized cell line and uses thereof |
-
2000
- 2000-08-18 US US09/641,471 patent/US7138262B1/en not_active Expired - Lifetime
-
2001
- 2001-08-17 NZ NZ537128A patent/NZ537128A/en not_active IP Right Cessation
- 2001-08-17 EP EP01964176.0A patent/EP1309340B1/en not_active Expired - Lifetime
- 2001-08-17 EP EP14170682.0A patent/EP2805727A1/en not_active Withdrawn
- 2001-08-17 EP EP10182992.7A patent/EP2292256B1/en not_active Expired - Lifetime
- 2001-08-17 CA CA2388041A patent/CA2388041C/en not_active Expired - Lifetime
- 2001-08-17 MX MXPA02003894A patent/MXPA02003894A/es active IP Right Grant
- 2001-08-17 NZ NZ519014A patent/NZ519014A/en not_active IP Right Cessation
- 2001-08-17 IL IL14902901A patent/IL149029A0/xx active IP Right Grant
- 2001-08-17 CN CN201210019823XA patent/CN102559633A/zh active Pending
- 2001-08-17 CN CNB018028012A patent/CN100352499C/zh not_active Expired - Lifetime
- 2001-08-17 AU AU85061/01A patent/AU785460B2/en not_active Expired
- 2001-08-17 CN CN2007101051513A patent/CN101085345B/zh not_active Expired - Lifetime
- 2001-08-17 WO PCT/US2001/025882 patent/WO2002015927A1/en not_active Ceased
- 2001-08-17 JP JP2002520848A patent/JP5008245B2/ja not_active Expired - Lifetime
- 2001-08-17 CN CN201410418047.XA patent/CN104312995A/zh active Pending
- 2001-08-17 CA CA2767054A patent/CA2767054C/en not_active Expired - Lifetime
- 2001-08-17 CA CA2767473A patent/CA2767473C/en not_active Expired - Lifetime
-
2002
- 2002-04-08 IL IL149029A patent/IL149029A/en unknown
-
2006
- 2006-10-17 US US11/581,979 patent/US10041137B2/en not_active Expired - Fee Related
-
2011
- 2011-08-08 JP JP2011173243A patent/JP5683407B2/ja not_active Expired - Fee Related
- 2011-08-08 JP JP2011173242A patent/JP5840890B2/ja not_active Expired - Fee Related
-
2014
- 2014-10-10 JP JP2014209206A patent/JP2015015964A/ja active Pending
-
2015
- 2015-06-10 HK HK15105530.9A patent/HK1205183A1/xx unknown
-
2016
- 2016-04-27 JP JP2016089304A patent/JP6659443B2/ja not_active Expired - Lifetime
-
2018
- 2018-01-05 JP JP2018000449A patent/JP6626133B2/ja not_active Expired - Lifetime
- 2018-05-09 JP JP2018090467A patent/JP6681428B2/ja not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016135146A5 (cg-RX-API-DMAC7.html) | ||
| JP2004506438A5 (cg-RX-API-DMAC7.html) | ||
| WO2016138534A3 (en) | Antisense-induced exon2 inclusion in acid alpha-glucosidase | |
| KR102021075B1 (ko) | 피로의 치료 또는 예방 방법 | |
| CA2388041A1 (en) | High mannose proteins and methods of making high mannose proteins | |
| HRP20200226T1 (hr) | Inhibitor glukozilceramid sintaze | |
| BR112012027062A2 (pt) | composto, processo para a preparação de um composto, método para prevenção e/ou tratamento de doenças e condições, e, composição farmacêutica | |
| RU2013155453A (ru) | Диверсификация молочных олигосахаридов человека (hmos) или их предшественников | |
| CN1720045A (zh) | 包含免疫调节化合物的组合物及使用该组合物治疗和控制骨髓增生性疾病的方法 | |
| BRPI0915928B8 (pt) | anticorpo isolado ou proteína funcional e composição farmacêutica compreendendo os mesmos | |
| WO2015031564A3 (en) | Substituted-1h-benzo[d]imidazole compounds as lysine-specific demethylase 1 (lsd1 ) inhibitors | |
| WO2019133770A3 (en) | Glycolate oxidase inhibitors for the treatment of disease | |
| BR112013020992A2 (pt) | aparelho e método para isolamento de leucócitos e células tumorosas por meio de filtração | |
| WO2013075116A3 (en) | Omega 7 rich compositions and methods of isolating omega 7 fatty acids | |
| MX2015008837A (es) | Composiciones parenterales estables de dnj. | |
| KR20120096402A (ko) | 암 치료용 선택적인 ep4 수용체 길항제 | |
| EP3911330B1 (en) | Dna-pkcs inhibitors for increasing genome editing efficiency | |
| ZA202310184B (en) | Crystalline forms of a pharmaceutical compound | |
| CN119451690A (zh) | 包含分泌组的rna及其使用方法 | |
| JP2024529510A (ja) | 新規ベンゼン誘導体およびその免疫抑制関連用途 | |
| WO2022192594A3 (en) | Nucleic acid molecules and vaccines comprising same for the prevention and treatment of coronavirus infections and disease | |
| WO2012124978A3 (ko) | 3차원 세포배양으로 수득한 조정 배지를 유효성분으로 포함하는 허혈성 질환 치료용 약학적 조성물 | |
| MX2023014776A (es) | Sales de sulcardina. | |
| BR112014014544A2 (pt) | usos de análogos de 4'-desferritiocina | |
| BR112021019139A2 (pt) | Célula de mamífero manipulada, composição, molécula isolada de dna de fita dupla, dispositivo implantável, cápsula de hidrogel, e, método de tratamento de um paciente com doença de fabry |